AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of the Aulea Veloxion™ Disposable Resectoscope System for Operational Efficiency in Surgical Management of Benign Prostatic Hyperplasia (BPH)

RecruitingNAAges 30 Years - 70 YearsMaleChinese University of Hong Kong
💬

In plain words

What the trial is, and whether it could suit you

Prospective, single-arm, single-site, post-market device study; all procedures use Veloxion™ per IFU.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Age 30-70 years old with symptomatic BPH. * Prostate volume 20-120 mL (TRUS/MRI/US) * Suitable for endoscopic resection/vaporization per device IFU. * Able to consent and comply with follow-up to 1 month. Exclusion Criteria: * Known/suspected prostate cancer requiring oncologic management. * Prior prostate surgery impacting urethral anatomy within 12 months. * Prior implant affecting urethral anatomy. * Active UTI or untreated bacteriuria pre-op. * Uncorrectable coagulopathy; inability to manage antithrombotics. * Severe medical comorbidity precluding anesthesia or endoscopy.
💊

What it tests

  • TURP using the Aulea Veloxion™ Disposable Resectoscope System
  • Aulea Veloxion™ Disposable Resectoscope System
📍

Where

1 site
Prince of Wales Hospital
Shatin, Hong Kong
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy